Teva's Copaxone sales see 12% spike; Vertex ups Kalydeco revenue guidance;

@FiercePharma: VCA ups 2015 guidance as 2Q sales and profits soar past expectations. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: As #Hospira expands recall of #ketorolac to 37M vials you've got to wonder what Pfizer thinks. Story | Follow @EricPFierce

@CarlyHFierce: Here's our latest at @FierceBiotech radio. I haven't listened to it yet, but someone told me it was good. Listen | Follow @CarlyHFierce

> Teva's ($TEVA) Copaxone sales rose 12% in Q2 despite new generic competition from Novartis' ($NVS) Glatopa. Report

> Vertex ($VRTX) upped its guidance for Kalydeco net revenue, now expecting $575 to $590 million for the year. Release

> India's Delhi High Court has dismissed a plea from AstraZeneca ($AZN) to block copies of diabetes drug Onglyza; the patent office will now decide whether to grant a compulsory license for the treatment. Report

> Alexion ($ALXN) hiked its revenue guidance to between $2.6 billion and $2.62 billion, up from a $2.55 billion to $2.6 billion range. Report

> The U.S. Senate Thursday used Valeant ($VRX) to lay out how U.S. tax laws have created an uneven playing field for some of America's largest companies. More

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA approves first weight-loss balloon, giving the obese a minimally invasive option. Article | Follow @FierceMedDev

@VarunSaxena2: FDA clears devices to reduce snoring in patients without sleep apnea. Report | Follow @VarunSaxena2

@EmilyWFierce: Indian diagnostics outfit debuts 'lab-on-cartridge' device for developing countries. More | Follow @EmilyWFierce

> In a big week for obesity devices, GI Dynamics terminates U.S. pivotal obesity device trial. More

> NeuWave Medical gets FDA clearance for software upgrade to its ablation system. News

Biotech News

@FierceBiotech: FierceBiotech Radio on Allergan's change in tune, Sanofi's new bet on Regeneron, and the latest big biotech IPO. Listen/Subscribe | Follow @FierceBiotech

@JohnCFierce: These Afrezza sales numbers say A: Afrezza isn't winning over many people and B: spurring any patient migrations in diabetes will be tough. | Follow @JohnCFierce

> Synergy Pharma jumps as second PhIII scores a success against constipation. More

> GlaxoSmithKline CEO's enthusiasm for R&D effort falls flat. Article

Vaccines News

> Pfizer's U.S. Prevnar 13 sales jump 87% in Q2. Report

> GSK envisions 'thoughtful, staged rollout' for Mosquirix. More

> Sanofi's dengue vax protects two-thirds of people aged 9 and up: NEJM. Story

> NIH's MERS vaccine looks promising in mice. Item

> Bavarian Nordic starts PhII of Prostvac in early-stage cancer. Article

CRO News

> Charles River's revenue slips on slumping R&D demand. More

> Covance names a new CEO as it adjusts to life with LabCorp. Story

> Patheon unloads some assets on the way to an IPO. Item

> PRA boosts its profit forecast after a strong sales quarter. Report

> Quintiles restores its rosy outlook after a big quarter. Article

Pharma Manufacturing News

> More cuts as Sun Pharma pulls Ranbaxy into the fold. Item

> Cardinal reports rising revenues and says next year looks even better. More

> McKesson reports higher Q1 revenues, but international sales were flat. Report

> FDA issues draft guidance on quality manufacturing metrics. Story

> Regulators in Europe propose bans on plants in China and India. Article

Pharma Asia News

> Is Asia's IP landscape in for big changes under TPP? Item

> India drugs watchdog to look at feasibility of online drug sales. More

> Syngene IPO by India's Biocon reaches top of range with no GVK, Quest blowback. Story

> More change ahead for Novogen as interim CEO Ross orders wide review of programs. Article

> S. Korea's Hanmi sells lung cancer candidate rights to BI in second major deal this year. Report

And Finally... Companies including Pfizer ($PFE) and Teva ($TEVA) are recruiting thousands of recreational drug users for trials of abuse-deterrent opioid candidates. More

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.